(Source: Emory University) Woodruff Health Sciences Center | Feb. 23, 2016 Results of the Phase II clinical trial were presented Feb. 23 at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART). Bone loss also leads to a higher rate of fracture in HIV-iinfected individuals. Results of the Phase II clinical trial were presented Feb. 23 at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Study co-authors were Igho...
↧